ArticleFrontiers in research metrics and analytics2026
Artificial intelligence to enhance research integrity in evidence-based medicine: toward scalable trustworthiness assessment.
Article in Frontiers in research metrics and analytics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fraudulent, falsified, and otherwise unreliable clinical research threatens the foundations of evidence-based medicine because systematic reviews, meta-analyses, and clinical practice guidelines depend on the trustworthiness of the studies they include. Retractions are increasing faster than publication output and often occur only after substantial delay, allowing problematic trials to be cited, pooled, and incorporated into downstream clinical recommendations. Recent evidence shows that retracted randomized trials have contaminated thousands of meta-analyses and hundreds of guideline documents, while only a small minority of affected reviews later self-correct. This is not only a clinical problem but also an integrity analytics problem: unreliable studies generate article-level, trial-level, and network-level signals that are not yet systematically integrated into evidence-synthesis workflows. Existing approaches can detect some image anomalies, textual irregularities, reporting inconsistencies, and statistical red flags, but important blind spots remain. Fabricated clinical datasets may appear statistically plausible, outcome switching often requires registration-publication comparison, and most available tools operate in isolation rather than as coordinated screening systems. We argue that the next generation of safeguards should combine AI/ML-based detection systems, statistical forensic methods, structured trustworthiness appraisal tools, and workflow-level screening frameworks within evidence synthesis. Embedding staged trustworthiness assessment early in systematic reviews, alongside stronger publisher- and database-level integrity infrastructure, could help prevent unreliable trials from distorting pooled estimates and downstream guidance. Such systems should support triage and prioritization rather than replace human judgment. Framed in this way, scalable trustworthiness assessment represents a practical research metrics and analytics agenda for strengthening the evidence ecosystem from primary studies to reviews, guidelines, and policy decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.